Literature DB >> 20556520

Peri-operative management of Cushing's disease.

Dima AbdelMannan1, Warren R Selman, Baha M Arafah.   

Abstract

Management of patients with ACTH producing pituitary adenoma remains to be challenging. Removal of the pituitary adenoma through transsphenoidal surgery is the main stay of treatment. Complete resection of the adenoma is followed by the development of ACTH deficiency since the normal corticotrophs are suppressed by the pre-existing hypercortisolemia. The concern for ACTH deficiency has led many centers to advocate the use glucocorticoids before, during and after surgery. We provide evidence that such coverage with glucocorticoids is unnecessary until clinical or biochemical documentation of need is established. Given that patients are closely monitored, they are immediately treated with glucocorticoids once they exhibit any clinical and/or biochemical evidence of adrenal insufficiency. Defining remission in the immediate postoperative period has been rather difficult despite using different biochemical markers. Serum cortisol continues to be the best determinant of disease activity after surgical adenomectomy. However it needs to be interpreted with caution as a biochemical marker of remission in patients given glucocorticoids during and after surgery. Other biochemical markers are also used in the peri-operative period to determine the possibility of remission. These include the dexamethasone suppression test, CRH stimulation without dexamethasone, urinary free cortisol measurements, desmopressin stimulation test, the determination of salivary cortisol and / or plasma ACTH concentrations. Each test has its own advantages and limitations. The simplest and most informative approach is to measure serum cortisol levels repeatedly after surgery without the administration of exogenous glucocorticoids. Low serum cortisol levels (less than 2 μg/dL) in the peri-operative period are highly indicative of surgical success and a high likelihood for clinical remission. Higher serum cortisol levels require careful interpretation and further planning and discussions between the patient and the management team.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556520     DOI: 10.1007/s11154-010-9140-6

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  34 in total

1.  ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome.

Authors:  D H NELSON; J W MEAKIN; G W THORN
Journal:  Ann Intern Med       Date:  1960-03       Impact factor: 25.391

2.  Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma.

Authors:  Ronald J Benveniste; Wesley A King; Jane Walsh; Jacob S Lee; Bradley N Delman; Kalmon D Post
Journal:  J Neurosurg       Date:  2005-06       Impact factor: 5.115

3.  Ketoconazole inhibits corticotropic cell function in vitro.

Authors:  G K Stalla; J Stalla; M Huber; J P Loeffler; V Höllt; K von Werder; O A Müller
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736

4.  Intraoperative adrenocorticotropin levels during transsphenoidal surgery for Cushing's disease do not predict cure.

Authors:  K E Graham; M H Samuels; H Raff; S L Barnwell; D M Cook
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

5.  Early repeat surgery for persistent Cushing's disease.

Authors:  Z Ram; L K Nieman; G B Cutler; G P Chrousos; J L Doppman; E H Oldfield
Journal:  J Neurosurg       Date:  1994-01       Impact factor: 5.115

Review 6.  Cushing's Syndrome: important issues in diagnosis and management.

Authors:  James W Findling; Hershel Raff
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

7.  Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results.

Authors:  Gary D Hammer; J Blake Tyrrell; Kathleen R Lamborn; Carol B Applebury; Elizabeth T Hannegan; Scott Bell; Riva Rahl; Amy Lu; Charles B Wilson
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

8.  Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases.

Authors:  Charlotte Höybye; Eva Grenbäck; Marja Thorén; Anna-Lena Hulting; Lars Lundblad; Hans von Holst; Anders Anggård
Journal:  J Neurosurg       Date:  2004-04       Impact factor: 5.115

9.  Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test.

Authors:  Joseph C T Chen; Aitun P Amar; SooHo Choi; Peter Singer; Wnluam T Couldwell; Martin H Weiss
Journal:  J Neurosurg       Date:  2003-05       Impact factor: 5.115

10.  Assessment of endocrine function after transsphenoidal surgery for Cushing's disease.

Authors:  D R McCance; D S Gordon; T F Fannin; D R Hadden; L Kennedy; B Sheridan; A B Atkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1993-01       Impact factor: 3.478

View more
  10 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection.

Authors:  Yana Stolyarov; James Mirocha; Adam N Mamelak; Anat Ben-Shlomo
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

3.  Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas.

Authors:  Abdelle F Cheres; Nadine ElAsmar; Aman Rajpal; Warren R Selman; Baha M Arafah
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

4.  Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease.

Authors:  David Asuzu; Grégoire P Chatain; Christina Hayes; Sarah Benzo; Raven McGlotten; Meg Keil; Andrea Beri; Susmeeta T Sharma; Lynnette Nieman; Maya Lodish; Constantine Stratakis; Russell R Lonser; Edward H Oldfield; Prashant Chittiboina
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

Review 5.  Approach to the postoperative patient with Cushing's disease.

Authors:  Martin J Rutkowski; Jonathan D Breshears; Sandeep Kunwar; Manish K Aghi; Lewis S Blevins
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 6.  Dynamic changes of views on the brain changes of Cushing's syndrome using different computer-assisted tool.

Authors:  Lu Gao; Lu Liu; Lin Shi; Yishan Luo; Zihao Wang; Xiaopeng Guo; Bing Xing
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

Review 7.  Detection of recurrent Cushing's disease: proposal for standardized patient monitoring following transsphenoidal surgery.

Authors:  Alejandro Ayala; Alex J Manzano
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

8.  Prognostic usefulness of ACTH in the postoperative period of Cushing's disease.

Authors:  Pablo Abellán-Galiana; Carmen Fajardo-Montañana; Pedro Riesgo-Suárez; Marcelino Pérez-Bermejo; Celia Ríos-Pérez; José Gómez-Vela
Journal:  Endocr Connect       Date:  2019-09       Impact factor: 3.335

9.  Perioperative Management of a Patient With Cushing Disease.

Authors:  Elena V Varlamov; Greisa Vila; Maria Fleseriu
Journal:  J Endocr Soc       Date:  2022-01-28

Review 10.  Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.

Authors:  Xin He; James W Findling; Richard J Auchus
Journal:  Pituitary       Date:  2022-04-26       Impact factor: 3.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.